Lyra Therapeutics Halts Drug Development, Cuts Entire Workforce

Lyra Therapeutics suspends LYR-210 development for chronic rhinosinusitis, lays off 28 employees, and explores strategic alternatives as stock plummets 44% in premarket trading.